检索结果-南通市图书馆

Characterization of a pangolin SARS-CoV-2-related virus isolate that uses the human ACE2 receptor

在线全文

学校读者我要写书评

暂无评论

Science China(life Sciences) 2024年第7期67卷 1502-1513页

作者： Luo-Yuan xia xue-Feng Wang xiao-ming Cui Yi-ming Zhang Zhen-Fei Wang En-Tao li chang-Fa Fan Ke Song Yuan-Guo li Run-Ze Ye Fang-xu li Dai-Yun Zhu Jie Zhang Zhuang-Zhuang Shi ming-Zhu Zhang liang-jing li Shi-jing Shen Song Jin Ya-Wei Zhang Wei-Guang Fu lin Zhao wen-hao Wang Tie-Cheng Wang You-Chun Wang Jia-Fu Jiang Yan-ling Hu Na Jia Yu-Wei Gao wu-Chun Cao Institute of EcoHealth School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012China changchun Veterinary Research Institute Changchun 130122China State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and EpidemiologyBeijing 100071China Division of Animal Model Research Institute for Laboratory Animal ResourcesNational Institutes for Food and Drug ControlBeijing 102629China National Institutes for Food and Drug Control Beijing 102629China life Sciences Institute Guangxi Medical UniversityNanning 530020China College of life Sciences Shandong Normal UniversityJinan 250014China Research Unit of Discovery and Tracing of Natural Focus Diseases Chinese Academy of Medical SciencesBeijing 100071China

Various SARS-CoV-2-related coronaviruses have been increasingly identified in pangolins,showing a potential threat to *** we report the infectivity and pathogenicity of the SARS-CoV-2-related virus,PCoV-GX/P2V,which was isolated from a Malayan pangolin(Manis javanica).PCoV-GX/P2V could grow in human hepatoma,colorectal adenocarcinoma cells,and human primary nasal epithelial *** replicated more efficiently in cells expressing human angiotensin-converting enzyme 2(hACE2)as SARS-CoV-2 *** intranasal inoculation to the hACE2-transgenic mice,PCoV-GX/P2V not only replicated in nasal turbinate and lungs,but also caused interstitial pneumonia,characterized by infiltration of mixed inflammatory cells and multifocal alveolar *** population immunity established by SARS-CoV-2 infection and vaccination may not protect people from PCoV-GX/P2V *** findings further verify the hACE2 utility of PCoV-GX/P2V by in vivo experiments using authentic viruses and highlight the importance for intensive surveillance to prevent possible cross-species transmission.

关键词： pangolin SARS-CoV-2-related virus infectivity pathogenicity human cell lines human ACE2 receptor hACE2-transgenic mice

The Lyman-alpha Solar Telescope(LST) for the ASO-S mission——Ⅱ. design of LST

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2019年第11期19卷 33-48页

作者： Bo Chen Hui li Ke-Fei Song Quan-Feng Guo Pei-Jie Zhang ling-Ping He Shuang Dai xiao-Dong Wang Hai-Feng Wang Chun-Long liu Hong-Ji Zhang Guang Zhang Yunqi Wang Shi-Jie liu Hong-Xin Zhang Lei liu Shi-Lei Mao Yang liu Jia-hao Peng Peng Wang liang Sun Yang liu Zhen-Wei Han Yan-Long Wang Kun wu Guang-Xing Ding Peng Zhou Xin Zheng ming-Yi xia Qing-wen wu Jin-Jiang Xie Ya Chen Shu-Mei Song Hong Wang Bo Zhu chang-Bo Chu wen-Gang Yang li Feng Yu Huang Wei-Qun Gan ying li jing-Wei li Lei Lu Jian-Chao xue Bei-li ying ming-Zhe Sun Cheng Zhu Wei-Min Bao Lei Deng Zeng-Shan yin changchun Institute of Optics FineMechanics and PhysicsChinese Academy of SciencesChangchun 130033China State Key Laboratory of Applied Optics Changchun 130033China Key Laboratory of Dark Matter and Space Astronomy Purple Mountain ObservatoryChinese Academy of SciencesNanjing 210034China School of Astronomy and Space Science University of Science and Technology of ChinaHefei 230026China Xi’an Institute of Optics and Precision Mechanics Chinese Academy of SciencesXi’an 710119China Shandong University Weihai 264209China Innovation Academy for Microsatellites Chinese Academy of SciencesShanghai 201210China

As one of the three payloads for the Advanced Space-based Solar Observatory(ASO-S)mission,the Lyman-alpha(Lyα)Solar Telescope(LST)is composed of three instruments:a Solar Corona Imager(SCI),a LyαSolar Disk Imager(SDI)and a full-disk White-light Solar Telescope(WST).When working in-orbit,LST will simultaneously perform high-resolution imaging observations of all regions from the solar disk to the inner corona up to 2.5 R⊙(R⊙stands for the mean solar radius)with a spatial resolution of 4.8′′and 1.2′′for coronal and disk observations,respectively,and a temporal resolution of 30–120 s and 1–120 s for coronal and disk observations,*** maximum exposure time can be up to20 s due to precise pointing and image stabilization *** the three telescopes of LST,SCI is a dual-waveband coronagraph simultaneously and independently observing the inner corona in the HI Lyα(121.6±10 nm)line and white light(WL)(700±40 nm)wavebands by using a narrowband Lyαbeam splitter and has a field of view(FOV)from 1.1 to 2.5 R⊙.The stray-light suppression level can attainline and 360.0 nm wavebands,respectively,which adopt an off-axis two-mirror reflective structure with an FOV up to 1.2 R⊙,covering the inner coronal edge area and relating to coronal *** present the up-to-date design for the LST payload.

关键词： telescopes—instrumentation high angular resolution—Sun flares—Sun coronal mass ejections(CMEs)—Sun UV radiation

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie wu Shu-wei duan Hong-tao Yang Yue-yi Deng Wei li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo Jun Zhu jing-ai Fang xu-sheng liu li-hua Wang Rong Wang Nian-song Wang xiao-hong Cheng li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping yin Geng-ru Jiang Hong-yu Chen wen-hu liu Hong-li lin Meng liang Lu Ma ming Chen li-qun Song Jian Chen Qing Zhu chang-ying Xing Yun li Ji-ning Gao Rong-shan li ying li hao Zhang ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pduction in urine protein *** with the losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第2期8卷 672-682页

作者： Nawal Al Kaabi Yun Kai Yang Yu liang Ke xu xue Feng Zhang Yun Kang Yu Qin Jin Jun Wei Hou jing Zhang Tian Yang Salah Hussein Mohamed Saif ElDein Ze Hua Lei hao Zhang Shuai Shao Zhao ming liu Ning liu xiang Zheng Ji Guo Su Sen Sen Yang xiangfeng Cong Yao Tan wenwen Lei xue Jun Gao Zhiwei Jiang Hui Wang Meng li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud xue Zhang chang Qu Dan ying liu jing Zhang Mengjie Yang Islam Eltantawy Peng xiao Fu Jie Shen Jin Juan wu Zi Bo Han li Fang du Fang Tang Shi Chen Zhi jing Ma Fan Zheng Ya Nan Hou Xin Yu li Xin li Zhao Nian Wang Jin liang yin xiao Yan Mao Jin Zhang liang Qu Yun Tao Zhang xiao ming Yang Guizhen wu Qi ming li Sheikh Khalifa Medical City SEHAAbu DhabiUAE College of Medicine and Health Sciences Khalifa UniversityAbu DhabiUAE China National Biotec Group Company limited BeijingChina The Sixth Laboratory National Vaccine and Serum Institute(NVSI)BeijingChina National Engineering Center for New Vaccine Research BeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and Prevention(China CDC)BeijingChina Clinical Medicine Office National Vaccine and Serum Institute(NVSI)BeijingChina Lanzhou Institute of Biological Products Company limited LanzhouChina Beijing Key Tech Statistical Consulting Co. LtdBeijingChina Beijing Institute of Biological Products Company limited BeijingChina Union 71 Abu DhabiUAE G42 Healthcare Abu DhabiUAE

An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to *** participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or *** primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating *** May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV *** results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or *** immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by *** findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages.

关键词： phase neutral spectrum

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第1期7卷 1-22页

作者： ying-Hui Jin lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui li Yi-Rong li Ke liang li-Kai lin li-Sha Luo jing Ma lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan xue-Qun Ren Hui-Min Sun ying Wang Yun-Yun Wang Hong weng Chao-Jie Wei Dong-Fang wu Jian xia Yong Xiong Hai-Bo xu xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye xiao-Chun Zhang ying-wen Zhang yin-Gao Zhang Hua-Min Zhang Yan Zhao ming-Juan Zhao hao Zi xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Hospital Management Wuhan UniversityWuhan 430071China Department of Respiratory Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Pharmacy Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institute of Evidence-Based Medicine and Knowledge Translation Henan UniversityKaifeng 475000China China Academy of Chinese Medical Sciences Beijing 100700China China Center for Evidence Based Traditional Chinese Medicine(CCEBTCM) Beijing 100700China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Infectious Diseases Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Medical Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Division of Nursing Affairs Zhongnan Hospital of Wuhan UniversityWuhan 430071China Office of Nosocomial Infection Control Zhongnan Hospital of Wuhan UniversityWuhan 430071China Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Health Research Methods Evidenceand ImpactMcMaster UniversityHamiltonON L8S 4L8Canada Department of Traditional Chinese Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Global Health Institute Wuhan UniversityWuhan 430072China the Zhongnan Hospital of wuhan University Novel Coronavirus Management and Research Team Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care(CPAM)

In December 2019, a new type viral pneumonia cases occurred in wuhan, Hubei Province;and then named "2019 novel coronavirus(2019-nCoV)" by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.

关键词： 2019 novel coronavirus 2019-nCoV Respiratory disease Pneumonia Infectious diseases Rapid advice guideline Clinical practice guideline Evidence-based medicine

Performances of a prototype point-contact germanium detector immersed in liquid nitrogen for light dark matter search

在线全文

学校读者我要写书评

暂无评论

Science China(Physics,Mechanics & Astronomy) 2019年第3期62卷 58-65页

作者： hao Jiang liTao Yang Qian Yue KeJun Kang JianPing Cheng Yuanjing li Henry Tsz-King Wong M.A?artio?lu HaiPeng An JianPing chang jingHan Chen YunHua Chen Zhi Deng Qiang du Hui Gong li He Jin Wei Hu QingDong Hu HanXiong Huang liPing Jia HauBin li Hong li Jian Min li Jin li xia li xueQian li YuLan li Bin liao FongKay lin ShinTed lin ShuKui liu YanDong liu YuanYuan liu ZhongZhi liu hao Ma jingLu Ma Hui Pan Jie Ren XiChao Ruan B.Sevda Vivek Sharma ManBin Shen Lakhwinder Singh Monoj Kumar Singh TianXi Sun changJian Tang WeiYou Tang Yang Tian GuangFu Wang JiMin Wang li Wang Qing Wang Yi Wang ShiYong wu YuCheng wu haoYang Xing yin xu Tao xue SongWei Yang Nan Yi Chunxu Yu HaiJun Yu JianFeng Yue XiongHui Zeng ming Zeng Zhi Zeng FengShou Zhang YunHua Zhang mingGang Zhao JiFang Zhou Zuying Zhou jingJun Zhu ZhongHua Zhu Key Laboratory of Particle and Radiation Imaging (Ministry of Education)and Department of Engineering Physics Tsinghua University College of Nuclear Science and Technology Beijing Normal University Institute of Physics Academia Sinica Department of Physics Dokuz Eylül University Department of Physics Tsinghua University NUCTECH Company Ya Long River Hydropower Development Company College of Physical Science and Technology Sichuan University Department of Nuclear Physics China Institute of Atomic Energy School of Physics Nankai University Department of Physics Banaras Hindu University Department of Physics Beijing Normal University

The CDEX-10 experiment searches for light weakly interacting massive particles, a form of dark matter, at the China Jinping Underground Laboratory, where approximately 10 kg of germanium detectors are arranged in an array and immersed in liquid nitrogen. Herein, we report on the experimental apparatus, detector characterization, and spectrum analysis of one prototype detector. Owing to the higher rise-time resolution of the CDEX-10 prototype detector as compared with CDEX-1 B, we identified the origin of an observed category of extremely fast events. For data analysis of the CDEX-10 prototype detector, we introduced and applied an improved bulk/surface event discrimination method. The results of the new method were compared to those of the CDEX-1 B spectrum. Both sets of results showed good consistency in the 0-12 ke Vee energy range, except for the 8.0 keV K-shell X-ray peak from the external copper.

关键词： WIMP pPCGe liquid nitrogen bulk/surface event discrimination extremely fast events

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li Luo Yong-Heng Zhao Gang Zhao li-Cai Deng xiao-Wei liu Yi-Peng jing Gang Wang hao-Tong Zhang Jian-Rong Shi xiang-Qun Cui Yao-Quan Chu Guo-Ping li Zhong-Rui Bai Yue wu Yan Cai Shu-Yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-Yuan Chen Jian-Jun Chen Kun-Xin Chen li Chen xue-Lei Chen xiao-Yan Chen ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong Bing du Dong-Wei Fan Lei Feng Jian-Ning Fu Peng Gao xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-wen Han Bo-liang He Jin-liang Hou Yong-Hui Hou wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-wen Hu Zhi-ying Huo Lei Jia Fang-Hua Jiang xiang Jiang Zhi-Bo Jiang Ge Jin xiao Kong xu Kong Ya-Juan Lei Ai-Hua li chang-Hua li Guang-Wei li Hai-Ning li Jian li Qi li Shuang li Sha-Sha li Xin-Nan li Yan li yin-Bi li Ye-Ping li Yuan liang Chien-Cheng lin Chao liu Gen-Rong liu Guan-Qun liu Zhi-Gang liu wen-Zhi Lu Yu Luo yin-dun Mao Heidi Newberg Ji-Jun Ni Zhao-xiang Qi Yong-Jun Qi Shi-yin Shen Huo-ming Shi jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang Hai Wang Hong-Chi Wang Jian Wang Jia-Ning Wang Jian-ling Wang Jian-Ping Wang Jun-xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang xia Wang Ya-Nan Wang You Wang Yue-Fei Wang You-Fen Wang Peng Wei ming-Zhi Wei Hong wu Ke-Fei wu xue-Bing wu Yu-Zhong wu xiao-Zheng Xing ling-Zhe xu Xin-Qi xu Yan xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang Hui-Qin Yang ming Yang Zheng-Qiu Yao Yong Yu Hui Yuan Hai-Bo Yuan Hai-Long Yuan Wei-Min Yuan Chao Zhai En-Peng Zhang Hua-Wei Zhang Jian-Nan Zhang li-Pin Zhang Wei Zhang Yong Zhang Yan-xia Zhang Zheng-Chao Zhang ming Zhao Fang Zhou xu Zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA Yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan liU Si Hong FAN Yi Pin wu Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN li ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI liang JIN Hai hao LEI xiao li Chun Yan li Min Qing li Qun Tang li xian Yong liU Hong De liU Jin Ping liU Zhang MA Yu Ting MAO Ya MO liu Fen NA Hui WANG jing Wei SONG Fang li SUN Sheng WANG Dong Ting WANG ming xuan WANG xiao Yan WANG yin Zhen WANG Yu Dong wu Wei wu Lan Ping xiaO Yan Hua XIE Hai Jun xu Hong ming xu Shou Fang xuE Rui xia YANG Chun YANG Kai Jun YUAN Sheng li ZHANG Gong Qi ZHANG Jin Bo ZHANG lin Song Zhao Shu Sen Zhao Wan ying ZHENG Kai ZHOU ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Data release of the LAMOST pilot survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2012年第9期12卷 1243-1246页

作者： A-li Luo hao-Tong Zhang Yong-Heng Zhao Gang Zhao xiang-Qun Cui Guo-Ping li Yao-Quan Chu Jian-Rong Shi Gang Wang Jian-Nan Zhang Zhong-Rui Bai xiao-Yan Chen Feng-Fei Wang Yan-Xin Guo Jian-Jun Chen Bing du xiao Kong Ya-Juan Lei yin-Bi li Yi-Han Song Yue wu Yan-xia Zhang Xin-lin Zhou Fang Zuo Peng du lin He wen Hou Yi-Qiao Dong Jian li Guang-Wei li Shuang li jing Song Yuan Tian Meng-Xin Wang Yong-Hui Hou Zhi-ying Huo Hong-Zhuan Hu Ning-Sheng Hu Zhong-wen Hu Lei Jia Fang-Hua Jiang xiang Jiang Zi-Bo Jiang Ge Jin Ai-Hua li Qi li yin-dun Mao Zheng-Hong Tang Qing-Sheng Tao liang-Ping Tu Da-Qing Wang Dan Wang Jian-Ping Wang Lei Wang Shou-Guan Wang Shu-Qing Wang Ya-Nan Wang You Wang Yue-Fei Wang ming-Zhi Wei xiang-xiang xue xiao-Zheng Xing ling-Zhe xu Xin-Qi xu Yan xu De-Hua Yang Shi-Hai Yang Zheng-Qiu Yao Yong Yu Hui Yuan Chao Zhai En-Peng Zhang jing Zhang li-Ping Zhang WeiZhang Yong Zhang Zhen-Chao Zhang ming Zhao Fang Zhou Yong-Tian Zhu Jie Zhu Si-Cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China lal @ lamost o rg Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Technologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

This paper describes the data release of the LAMOST pilot survey, which includes data reduction, calibration, spectral analysis, data products and data access. The accuracy of the released data and the information about the FITS headers of spectra are also introduced. The released data set includes 319 000 spectra and a catalog of these objects.

关键词： techniques: spectroscopic survey — data reduction — data release